{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:29:51Z","timestamp":1770485391709,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T00:00:00Z","timestamp":1395619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Risks and benefits of protease inhibitor (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>) (telaprevir or boceprevir) triple therapy in hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)\u2010infected patients with mildly decompensated cirrhosis, including those wait\u2010listed for liver transplantation (<jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content>), are incompletely known.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess virological responses and safety of <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content> triple therapy in patients with mildly decompensated Child\u2010Pugh (<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> \u22656 vs. compensated (<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>\u00a0=\u00a05) cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Multicentre cohort of 160 adults with cirrhosis treated with peginterferon\/ribavirin (peg\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) plus telaprevir (69%) or boceprevir (31%), comparing outcomes between those with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>\u00a0=\u00a05 and <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> \u22656.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients, 47% with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> \u22656 cirrhosis (<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> range 6\u201310), received <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content> triple therapy for a targeted duration of 48\u00a0weeks. The cohort was median age 59\u00a0years, 32% female, 59% genotype 1a, 35% previous null\/partial responders. Sustained virological response at 12\u00a0weeks (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12) was achieved by 35% of patients with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> \u22656 vs. 54% of those with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>\u00a0=\u00a05 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.02). <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>\u00a0=\u00a05, achievement of rapid virological response and genotype 1b\/other, independently predicted <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. Compared to those with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>\u00a0=\u00a05, patients with <jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> \u22656 had more peg\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> dose reductions, eltrombopag use, transfusions and hospitalisations to manage adverse events (all <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). Overall, 67 (42%) discontinued treatment early. Nine wait\u2010listed patients were treated for a median of 97\u00a0days (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 60\u2013160) prior to liver transplantation and five achieved post\u2010<jats:styled-content style=\"fixed-case\">LT SVR<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the presence of mild decompensation (Child\u2010Pugh \u22656), <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 rates with protease inhibitor triple therapy are significantly reduced and adverse events increased. Thus, treatment with protease inhibitor triple therapy, if judged as necessary, should be undertaken with close monitoring and awareness of the significant risks.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12718","type":"journal-article","created":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T04:22:58Z","timestamp":1395634978000},"page":"1213-1224","source":"Crossref","is-referenced-by-count":24,"title":["Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis"],"prefix":"10.1111","volume":"39","author":[{"given":"V.","family":"Saxena","sequence":"first","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Manos","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Registry Division of Research Kaiser Permanente Northern California Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. S.","family":"Yee","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"},{"name":"Veterans Affairs Medical Center San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Catalli","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Wayne","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Registry Division of Research Kaiser Permanente Northern California Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. A.","family":"Shvachko","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Registry Division of Research Kaiser Permanente Northern California Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Pauly","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Registry Division of Research Kaiser Permanente Northern California Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Chua","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Monto","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"},{"name":"Veterans Affairs Medical Center San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A.","family":"Terrault","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26194"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450170079026"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50073"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"e_1_2_7_9_1","volume-title":"Incivek [telaprevir]"},{"key":"e_1_2_7_10_1","volume-title":"Victrelis [boceprevir]","year":"2011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3283534d64"},{"key":"e_1_2_7_12_1","volume-title":"Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2007 California Health Interview Survey","author":"Gordon N","year":"2012"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.82.5.703"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.48"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12544"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v5.i9.496"},{"key":"e_1_2_7_17_1","volume-title":"Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Lawitz E","year":"2013"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"e_1_2_7_19_1","volume-title":"Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Curry M","year":"2013"},{"key":"e_1_2_7_20_1","volume-title":"Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Jacobson I","year":"2013"},{"key":"e_1_2_7_21_1","volume-title":"Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Zeuzem S","year":"2013"},{"key":"e_1_2_7_22_1","volume-title":"Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections","author":"Lawitz E","year":"2013"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04025.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.11.015"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.002"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50207"},{"key":"e_1_2_7_27_1","volume-title":"48th Annual Meeting of the European Association for the Study of the Liver","author":"Fontaine H","year":"2013"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12560"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12494"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.011"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280535"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.057893"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200104000-00004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.015"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.31"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12018"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00310-6"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25976"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12718","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:04:13Z","timestamp":1695571453000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,24]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/apt.12718"],"URL":"https:\/\/doi.org\/10.1111\/apt.12718","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,24]]}}}